QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortinet

MarketAxess Holdings

Ollie's Bargain Outlet Hlds

Zoom Video

Here we discuss five stocks that have gained more than 25% year to date and are well-poised to grow further, irrespective of the shape the economy takes to recover from COVID-19-induced recession.

5 Must-Buy Stocks No Matter What Shape Recovery Takes

Kopin

Livongo Health Inc

Novavax

The tech-heavy Nasdaq Composite Index has outperformed so far this year, having gained 12% in comparison to losses of 3.5%for the S&P 500 and 8.8% for Dow Jones.

5 Top-Ranked Stocks That Made Nasdaq Outperform in 1H

Datadog

Zscaler

Here we discuss five Nasdaq-listed stocks that have gained more than 100% year to date and are well-poised to grow further on solid prospects.

5 Nasdaq Stocks That Have Returned More Than 100% YTD

Celldex Therapeutics

Ideaya Biosciences Inc

Here's what pushed up shares of the highest-flying healthcare stocks.

3 Healthcare Stocks That Surged Last Week

Quidel (QDEL) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Why Quidel (QDEL) Is a Great Growth Stock

As of late, it has definitely been a great time to be an investor of Quidel

Will Quidel Continue to Surge Higher?

Beyond Meat

DocuSign

Tesla

Not all stocks succumbed to last week's market rout that ended the more than 10-week long rally. A few stocks popped last week.

5 High-Flying Stocks of Last Week That Defied Market Turmoil

CrowdStrike

eBay

JD.com

Here we pick five stocks that trade on Nasdaq and are positioned to grow as the index's rally continues in June.

Nasdaq's Rally Continues Unabated: 5 Hot Picks

Bio-Rad Laboratories

Veeva Systems

Vertex Pharmaceuticals

The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.

Why Coronavirus Test Firms Are Among 4 Key Health Care Stocks

The stock's been cooling off in recent weeks, and now could be an opportunity for investors to buy the dip.

Quidel Stock Is Up 130% This Year: Is This Coronavirus Stock Still a Hot Buy?

Quidel (QDEL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Quidel (QDEL): Strong Industry, Solid Earnings Estimate Revisions

Atlas Air Worldwide

Bandwidth

Chegg

Wayfair

Market's momentum is likely to continue in the coming months as the global economy will gather pace after nearly three months of lockdowns.

5 Top Momentum Stocks for June as U.S. Economy Reopens

BJ`s Wholesale Club Holdings Inc

Sprouts Farmers Markets

The coronavirus-induced concerns are persisting and a vaccine is yet to be developed. Despite this, Wall Street bulls are raging forward.

Major Indexes Regain Crucial Milestones: 5 Top Growth Picks

Everbridge

Eli Lilly

These fast movers are currently witnessing a short-term pullback in price. So, this could be a solid entry point for garnering better returns.

Top 4 Momentum Anomaly Stocks to Enhance Portfolio Returns

Bristol-Myers

Neurocrine Biosciences

Teladoc

Tandem Diabetes Care

Several top health care stocks are in buy zones or setting up, including Teladoc and Neurocrine Biosciences. They are all worth adding to your watchlist.

Teladoc, Bristol Myers, Quidel, Neurocrine Bio, Tandem Diabetes: 5 Health Stocks To Monitor Closely

Diagnostics company Quidel is launching a new type of coronavirus test that looks for antigens. It could be faster, easier to use and cheaper to produce than its any of its predecessors.

How Quidel's New Test Could Be A Game-Changer In Coronavirus

Quidel (QDEL) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Can Quidel (QDEL) Run Higher on Strong Earnings Estimate Revisions?

Dropbox

Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."

Major Indexes Defying "Sell in May" Adage: 5 Growth Picks

Quidel (QDEL) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Quidel (QDEL) in Focus: Stock Moves 6.2% Higher

Quidel (QDEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Looking for a Growth Stock? 3 Reasons Why Quidel (QDEL) is a Solid Choice

The diagnostics company's rapid point-of-care test for COVID-19 received an emergency use authorization from the FDA.

Here's Why Quidel Stock Is Soaring Today

Diagnostics company Quidel gained the Food and Drug Administration's blessing to sell a new type of coronavirus test that looks for antigens — sending Quidel stock rocketing Monday.

The Simplest Coronavirus Test Yet? Diagnostics Stock Flies On FDA Blessing

Nautilus

Pluralsight Inc - Ordinary Shares - Class A

Sunopta

Vista Outdoor

As the U.S. economy prepares to reopen, here are five growth stocks to invest in to earn significantly higher returns.

5 Stocks to Buy as America Prepares to Reopen Economy

Clorox

Moderna

Market's worst is behind us as negative estimates are already factored in valuations.

An Outstanding Week for Market Amid Record Job Losses: 5 Picks

Quidel Corporation's (NASDAQ: QDEL) development of an antigen test for the novel coronavirus (COVID-19) is a "game changer" in the world's fight against the pandemic, former Food and Drugs Administration commissioner Scott Gottlieb told CBS on Sunday.

Quidel's Recently Approved Antigen Test For Coronavirus Is 'Game Changer,' Former FDA Chief Says

News for QuidelOrtho Corp Stock (QDEL)